|
|
Article: ASCEND Therapeutics Announces Results from Phase 2 Cyclic Breast Pain Study; Company's Transdermal 4-OHT Therapy was Well Tolerated and Reduced Breast Pain in Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- December 8, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HERNDON, Va., Dec. 8 /PRNewswire/ -- ASCEND Therapeutics, a leading researcher and developer of pharmaceutical transdermal therapies for the treatment of chronic conditions, today announced that its investigational transdermal 4-OHT gel reduced cyclic breast pain among premenopausal women, based on preliminary results obtained from a Phase 2 clinical study.
Cyclic breast pain is a potentially debilitating chronic disorder that causes significant pain while impacting everyday activities such as athletics, sexual intimacy, and social or professional activities. Cyclic breast pain, or mastalgia, is defined clinically as significant breast pain lasting more than ...
Related newspaper, magazine, and journal articles:
|
|
Article: ASCEND Therapeutics, Inc. to Present at BIO 2003 ...
Business Wire;
June 20, 2003 ;
541 words
... ... June 20, 2003 ASCEND Therapeutics announced today ... President and CEO of ASCEND Therapeutics, Inc., is scheduled ... Herndon, Virginia, ASCEND Therapeutics, Inc. is a biopharmaceutical ... impact on cyclic breast pain and mammographic ...
|
|